Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators.
Immune-related adverse events
Immunotherapy
Renal cell carcinoma
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
03 08 2021
03 08 2021
Historique:
received:
06
05
2021
accepted:
23
07
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
6
8
2021
Statut:
epublish
Résumé
Severe immune-related Adverse Events (irAEs) develop in 10-27% of patients treated with Immune-Oncology (IO) [Powles (Lancet 391:748-757, 2018); Galsky (Lancet 395:1547-1557, 2020); Haanen (Ann Oncol 28:119-142, 2017)]. The aim of our study was to evaluate efficacy and clinical outcome of metastatic renal cell carcinoma (mRCC) patients who stopped Immune Checkpoint Inhibitors (ICIs) due to early Grade (G) 3-G4 irAEs. We retrospectively collected data from 204 mRCC patients treated with ICIs in 6 Italian referral centers adhering to the Meet-Uro group, between February 2017 and January 2020. To properly weight the results, patients who did not report early G3-G4 toxicities have been included as control group. Primary endpoint was to evaluate 6 months Progression Free Survival (PFS) after early treatment interruption for Grade (G) 3-4 toxicities compared to the control group. Secondary endpoints were to evaluate Time to treatment failure (TTF) and overall survival (OS) in both groups. All statistical analyses were performed using SPSS software (version 19.00, SPSS, Chicago). 18/204 (8.8%) patients had early treatment interruption for serious (G3-G4) irAEs. Early was defined as interruption of IO after only one or two administrations. Immune related nephritis and pancreatitis were the most common irAE that lead to treatment interruption. 6/18 patients received IO-IO combination whereas 12/18 patients antiPD1. In the study group, 12/18 (66.6%) were free from progression at 6 months since IO interruption, TTF was 1.6 months (95% CI 1.6-2.1), mPFS was 7.4 months (95% CI 3.16-11.6) and mOS was 15.5 months (5.1-25.8). In the control group 111/184 (60.3%) patients were free from progression at 6 months, TTF was 4.6 months (95% CI 3.5-5.6), mPFS was 4.6 months (95% CI 3.5-5.6) and mOS was 19.6 months (95% CI 15.1-24.0). In the overall population, mPFS was 5.0 months (95% CI 4.0-5.9) and mOS was 19.6 months (95% CI 15.1-24.0). ICIs seem to maintain efficacy even after early interruption due to severe irAE.
Sections du résumé
BACKGROUND
Severe immune-related Adverse Events (irAEs) develop in 10-27% of patients treated with Immune-Oncology (IO) [Powles (Lancet 391:748-757, 2018); Galsky (Lancet 395:1547-1557, 2020); Haanen (Ann Oncol 28:119-142, 2017)]. The aim of our study was to evaluate efficacy and clinical outcome of metastatic renal cell carcinoma (mRCC) patients who stopped Immune Checkpoint Inhibitors (ICIs) due to early Grade (G) 3-G4 irAEs.
METHODS
We retrospectively collected data from 204 mRCC patients treated with ICIs in 6 Italian referral centers adhering to the Meet-Uro group, between February 2017 and January 2020. To properly weight the results, patients who did not report early G3-G4 toxicities have been included as control group. Primary endpoint was to evaluate 6 months Progression Free Survival (PFS) after early treatment interruption for Grade (G) 3-4 toxicities compared to the control group. Secondary endpoints were to evaluate Time to treatment failure (TTF) and overall survival (OS) in both groups. All statistical analyses were performed using SPSS software (version 19.00, SPSS, Chicago).
RESULTS
18/204 (8.8%) patients had early treatment interruption for serious (G3-G4) irAEs. Early was defined as interruption of IO after only one or two administrations. Immune related nephritis and pancreatitis were the most common irAE that lead to treatment interruption. 6/18 patients received IO-IO combination whereas 12/18 patients antiPD1. In the study group, 12/18 (66.6%) were free from progression at 6 months since IO interruption, TTF was 1.6 months (95% CI 1.6-2.1), mPFS was 7.4 months (95% CI 3.16-11.6) and mOS was 15.5 months (5.1-25.8). In the control group 111/184 (60.3%) patients were free from progression at 6 months, TTF was 4.6 months (95% CI 3.5-5.6), mPFS was 4.6 months (95% CI 3.5-5.6) and mOS was 19.6 months (95% CI 15.1-24.0). In the overall population, mPFS was 5.0 months (95% CI 4.0-5.9) and mOS was 19.6 months (95% CI 15.1-24.0).
CONCLUSIONS
ICIs seem to maintain efficacy even after early interruption due to severe irAE.
Identifiants
pubmed: 34344414
doi: 10.1186/s12967-021-03008-9
pii: 10.1186/s12967-021-03008-9
pmc: PMC8330118
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
328Informations de copyright
© 2021. The Author(s).
Références
Nat Rev Rheumatol. 2016 Oct;12(10):593-604
pubmed: 27539666
JAMA Oncol. 2016 Feb;2(2):234-40
pubmed: 26633184
Ann Oncol. 2017 Feb 1;28(2):368-376
pubmed: 27687304
Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):266-71
pubmed: 21173239
Ann Intern Med. 2018 Jan 16;168(2):121-130
pubmed: 29297009
Front Pharmacol. 2017 Feb 08;8:49
pubmed: 28228726
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Eur J Cancer. 2017 Apr;75:24-32
pubmed: 28214654
Lancet. 2020 May 16;395(10236):1547-1557
pubmed: 32416780
Am J Clin Oncol. 2021 Mar 1;44(3):121-125
pubmed: 33617179
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
J Immunother Cancer. 2015 Sep 15;3:39
pubmed: 26380086
Eur J Cancer. 2019 Mar;109:21-27
pubmed: 30682533
J Thorac Oncol. 2017 Dec;12(12):1798-1805
pubmed: 28939128
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
Cancer. 2020 Sep 15;126(18):4156-4167
pubmed: 32673417
Front Oncol. 2020 Aug 12;10:1644
pubmed: 32903369
N Engl J Med. 2015 Jul 16;373(3):288-90
pubmed: 26176400
Arthritis Rheumatol. 2019 Dec;71(12):2100-2111
pubmed: 31379105
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921